- Home
- RPID vs AVTX Comparison
RPID vs AVTX Comparison
Compare RPID & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPID
- AVTX
- Stock Information
- Founded
- RPID 2006
- AVTX 2011
- Country
- RPID United States
- AVTX United States
- Employees
- RPID N/A
- AVTX N/A
- Industry
- RPID Medical Specialities
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RPID Health Care
- AVTX Health Care
- Exchange
- RPID Nasdaq
- AVTX Nasdaq
- Market Cap
- RPID 138.9M
- AVTX 118.6M
- IPO Year
- RPID 2021
- AVTX 2015
- Fundamental
- Price
- RPID $2.85
- AVTX $9.88
- Analyst Decision
- RPID Strong Buy
- AVTX Strong Buy
- Analyst Count
- RPID 2
- AVTX 8
- Target Price
- RPID $8.00
- AVTX $31.00
- AVG Volume (30 Days)
- RPID 105.5K
- AVTX 338.8K
- Earning Date
- RPID 08-12-2025
- AVTX 08-07-2025
- Dividend Yield
- RPID N/A
- AVTX N/A
- EPS Growth
- RPID N/A
- AVTX N/A
- EPS
- RPID N/A
- AVTX N/A
- Revenue
- RPID $30,289,000.00
- AVTX $441,000.00
- Revenue This Year
- RPID $17.94
- AVTX N/A
- Revenue Next Year
- RPID $20.55
- AVTX N/A
- P/E Ratio
- RPID N/A
- AVTX N/A
- Revenue Growth
- RPID 22.57
- AVTX N/A
- 52 Week Low
- RPID $0.80
- AVTX $3.39
- 52 Week High
- RPID $4.50
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- RPID 43.63
- AVTX 76.24
- Support Level
- RPID $2.40
- AVTX $8.41
- Resistance Level
- RPID $3.59
- AVTX $9.80
- Average True Range (ATR)
- RPID 0.29
- AVTX 0.85
- MACD
- RPID -0.05
- AVTX -0.01
- Stochastic Oscillator
- RPID 35.16
- AVTX 87.52
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).